Wednesday, August 30, 2017 7:23:37 AM
PREVECEUTICAL MEDICAL AND SPORTS 1 MARKETING ANNOUNCE JOINT VENTURE TO DEVELOP A THERAPY FOR CONCUSSIONS
https://sports1marketing.com/
Preveceutical, Sports 1 to develop concussion therapy
2017-08-30 06:34 ET - News Release
Mr. Stephen Van Deventer reports
PREVECEUTICAL MEDICAL AND SPORTS 1 MARKETING ANNOUNCE JOINT VENTURE TO DEVELOP A THERAPY FOR CONCUSSIONS
Preveceutical Medical Inc. and Sports 1 Marketing (S1M) have entered a joint venture to develop a therapy geared toward athletes who suffer from concussions (mild traumatic brain injury) (TBI).
Through PreveCeutical's current Research and Development program connected to the Caribbean Blue Scorpion venom, PreveCeutical and S1M believe that there is therapeutic potential in the peptides and proteins to potentially treat TBI.
According to the Centers for Disease Control and Prevention website, a severe TBI not only impacts the life of an individual and their family, but it also has a large societal and economic toll. The estimated economic cost of TBI in 2010, including direct and indirect medical costs, is estimated to be approximately $76.5 billion. Additionally, the cost of fatal TBIs and TBIs requiring hospitalization, many of which are severe, account for approximately 90% of the total TBI medical costs.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are encouraged from the fact that the Caribbean Blue Scorpion venom peptides bypasses the blood brain barrier and attaches to the abnormal cells, this is an indicator that we are going in the right direction. We are delighted to have this opportunity of working with S1M on this exciting program where we hope to be able to help millions of people. David Meltzer and Warren Moon are icons in the professional sports industry. Their vision to help a lot of people are identical to ours."
S1M's Co-Founder and CEO, David Meltzer commented, "With PreveCeutical's outstanding research and leadership team, we are excited to be partnered up with such an innovative and industry leading group of people."
Completion of the joint venture will be subject to a number of conditions including the approval of the Canadian Securities Exchange.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive therapies utilizing organic and nature identical products.
The Company currently has one product available for sale, the CELLB9trademark Immune System Booster. CELLB9trademark is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
Recent PRVCF News
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM